The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 331:1528-1529 December 1, 1994 Number 22
NextNext

Plasma Endothelin-1 and Doxorubicin Cardiotoxicity

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
To the Editor: Doxorubicin is a widely used and effective antineoplastic agent. However, doxorubicin therapy is limited by dose-dependent cardiotoxicity that may lead to congestive heart failure.1 To optimize doxorubicin therapy, it is important to detect early signs of cardiac toxicity. To measure the severity of myocardial damage and dysfunction, cardiac catheterization and endomyocardial biopsy have been used, as have electrocardiography, echocardiography, and radionuclear angiography. However, these methods all have limitations, are inadequate for the serial monitoring of individual patients, or both.

Levels of endothelin-1 peptide are transiently increased after physical stress.2,3 While studying sequential changes in plasma endothelin-1 levels . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.